Novome Biotechnologies
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Novome engineered gut bacteria to carry out defined functions as potential disease treatments.
02 / Novome Biotechnologies FAILURE REASONS
Failure reasons
The company said its research had not produced enough data to give it confidence in the therapeutic approach. It therefore decided to stop development, wind down operations and return remaining capital, rather than continue without that scientific support.
03 / EVENT HISTORY
Events in the structured record
- Closure announced
The company announced that it would discontinue its efforts and return remaining capital. The accessible announcement does not display an absolute publication date.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Research did not provide the required supporting data
- 02
Company chose to discontinue the therapeutic approach
- 03
Operations wound down and remaining capital to be returned